{"id":41554,"date":"2025-09-16T16:51:00","date_gmt":"2025-09-16T08:51:00","guid":{"rendered":"https:\/\/flcube.com\/?p=41554"},"modified":"2025-09-16T16:51:02","modified_gmt":"2025-09-16T08:51:02","slug":"haisco-pharma-secures-nmpa-approval-for-anrikefon-in-hemodialysis%e2%80%91related-pruritus","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=41554","title":{"rendered":"Haisco Pharma Secures NMPA Approval for Anrikefon in Hemodialysis\u2011Related Pruritus"},"content":{"rendered":"\n<p><strong>Haisco Pharmaceutical Group Co., Ltd. (<a href=\"https:\/\/www.google.com\/finance\/quote\/002653:SHE\">SHE: 002653<\/a>)<\/strong> announced that the <strong>China National Medical Products Administration (NMPA)<\/strong> has granted additional approval for its Category\u202f1 innovative drug, <strong>Anrikefon Injection<\/strong> (trade name: <em>Sishujing<\/em>, development code: HSK21542). The new indication covers moderate\u2011to\u2011severe pruritus in adult patients with chronic kidney disease (CKD) undergoing maintenance hemodialysis.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-drug-profile\">Drug Profile<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism<\/strong> \u2013 Anrikefon is a highly selective peripheral <strong>\u03ba\u2011opioid receptor (KOR) agonist<\/strong> developed independently by Haisco Pharma.<\/li>\n\n\n\n<li><strong>Clinical Data<\/strong> \u2013 Phase\u202f2 trials show that Anrikefon significantly reduces pruritus, outperforming placebo on both primary and secondary endpoints while maintaining a favorable safety profile.<\/li>\n\n\n\n<li><strong>Existing Approvals<\/strong> \u2013 The drug was first approved in May\u202f2025 for mild\u2011to\u2011moderate pain after abdominal surgery.<\/li>\n\n\n\n<li><strong>Ongoing Studies<\/strong> \u2013 A Phase\u202f3 program evaluating Anrikefon for postoperative analgesia after orthopedic surgery is progressing smoothly.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-market-significance\">Market Significance<\/h4>\n\n\n\n<p>Pruritus is a common, debilitating symptom in CKD patients on hemodialysis, with limited effective therapies. The NMPA approval positions Anrikefon as a first\u2011in\u2011class treatment in China\u2019s growing CKD therapeutics market, projected to reach <strong>$3.2\u202fbillion<\/strong> by 2030.<\/p>\n\n\n\n<p>Haisco Pharma\u2019s strategic focus on peripheral opioid pathways aligns with global trends toward safer, non\u2011central nervous system\u2011acting analgesics, potentially expanding the drug\u2019s appeal beyond China.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-company-outlook\">Company Outlook<\/h4>\n\n\n\n<p>Haisco\u2019s robust pipeline and strong regulatory track record reinforce its reputation as a leading innovator in China\u2019s biopharmaceutical sector. The new approval for Anrikefon is expected to accelerate revenue growth and strengthen the company\u2019s presence in the nephrology and pain management markets.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/\u6d77\u601d\u79d1\uff1a\u5173\u4e8e1\u7c7b\u521b\u65b0\u836f\u5b89\u745e\u514b\u82ac\u6ce8\u5c04\u6db2\u65b0\u9002\u5e94\u75c7\u83b7\u6279\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u6d77\u601d\u79d1\uff1a\u5173\u4e8e1\u7c7b\u521b\u65b0\u836f\u5b89\u745e\u514b\u82ac\u6ce8\u5c04\u6db2\u65b0\u9002\u5e94\u75c7\u83b7\u6279\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-febf931f-8795-41b0-9683-a4536a052fef\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/\u6d77\u601d\u79d1\uff1a\u5173\u4e8e1\u7c7b\u521b\u65b0\u836f\u5b89\u745e\u514b\u82ac\u6ce8\u5c04\u6db2\u65b0\u9002\u5e94\u75c7\u83b7\u6279\u7684\u516c\u544a.pdf\">\u6d77\u601d\u79d1\uff1a\u5173\u4e8e1\u7c7b\u521b\u65b0\u836f\u5b89\u745e\u514b\u82ac\u6ce8\u5c04\u6db2\u65b0\u9002\u5e94\u75c7\u83b7\u6279\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/\u6d77\u601d\u79d1\uff1a\u5173\u4e8e1\u7c7b\u521b\u65b0\u836f\u5b89\u745e\u514b\u82ac\u6ce8\u5c04\u6db2\u65b0\u9002\u5e94\u75c7\u83b7\u6279\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-febf931f-8795-41b0-9683-a4536a052fef\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) announced that the China National Medical Products Administration&#8230;<\/p>\n","protected":false},"author":1,"featured_media":41556,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[139,15,929],"class_list":["post-41554","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-haisco-pharmaceutical","tag-product-approvals","tag-she-002653"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Haisco Pharma Secures NMPA Approval for Anrikefon in Hemodialysis\u2011Related Pruritus - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) announced that the China National Medical Products Administration (NMPA) has granted additional approval for its Category\u202f1 innovative drug, Anrikefon Injection (trade name: Sishujing, development code: HSK21542). The new indication covers moderate\u2011to\u2011severe pruritus in adult patients with chronic kidney disease (CKD) undergoing maintenance hemodialysis.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=41554\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Haisco Pharma Secures NMPA Approval for Anrikefon in Hemodialysis\u2011Related Pruritus\" \/>\n<meta property=\"og:description\" content=\"Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) announced that the China National Medical Products Administration (NMPA) has granted additional approval for its Category\u202f1 innovative drug, Anrikefon Injection (trade name: Sishujing, development code: HSK21542). The new indication covers moderate\u2011to\u2011severe pruritus in adult patients with chronic kidney disease (CKD) undergoing maintenance hemodialysis.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=41554\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-16T08:51:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-16T08:51:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1606.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41554#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41554\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Haisco Pharma Secures NMPA Approval for Anrikefon in Hemodialysis\u2011Related Pruritus\",\"datePublished\":\"2025-09-16T08:51:00+00:00\",\"dateModified\":\"2025-09-16T08:51:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41554\"},\"wordCount\":258,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41554#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1606.webp\",\"keywords\":[\"Haisco Pharmaceutical\",\"Product approvals\",\"SHE: 002653\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=41554#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41554\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=41554\",\"name\":\"Haisco Pharma Secures NMPA Approval for Anrikefon in Hemodialysis\u2011Related Pruritus - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41554#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41554#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1606.webp\",\"datePublished\":\"2025-09-16T08:51:00+00:00\",\"dateModified\":\"2025-09-16T08:51:02+00:00\",\"description\":\"Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) announced that the China National Medical Products Administration (NMPA) has granted additional approval for its Category\u202f1 innovative drug, Anrikefon Injection (trade name: Sishujing, development code: HSK21542). The new indication covers moderate\u2011to\u2011severe pruritus in adult patients with chronic kidney disease (CKD) undergoing maintenance hemodialysis.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41554#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=41554\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41554#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1606.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1606.webp\",\"width\":1080,\"height\":608,\"caption\":\"Haisco Pharma Secures NMPA Approval for Anrikefon in Hemodialysis\u2011Related Pruritus\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41554#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Haisco Pharma Secures NMPA Approval for Anrikefon in Hemodialysis\u2011Related Pruritus\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Haisco Pharma Secures NMPA Approval for Anrikefon in Hemodialysis\u2011Related Pruritus - Insight, China&#039;s Pharmaceutical Industry","description":"Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) announced that the China National Medical Products Administration (NMPA) has granted additional approval for its Category\u202f1 innovative drug, Anrikefon Injection (trade name: Sishujing, development code: HSK21542). The new indication covers moderate\u2011to\u2011severe pruritus in adult patients with chronic kidney disease (CKD) undergoing maintenance hemodialysis.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=41554","og_locale":"en_US","og_type":"article","og_title":"Haisco Pharma Secures NMPA Approval for Anrikefon in Hemodialysis\u2011Related Pruritus","og_description":"Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) announced that the China National Medical Products Administration (NMPA) has granted additional approval for its Category\u202f1 innovative drug, Anrikefon Injection (trade name: Sishujing, development code: HSK21542). The new indication covers moderate\u2011to\u2011severe pruritus in adult patients with chronic kidney disease (CKD) undergoing maintenance hemodialysis.","og_url":"https:\/\/flcube.com\/?p=41554","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-16T08:51:00+00:00","article_modified_time":"2025-09-16T08:51:02+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1606.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=41554#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=41554"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Haisco Pharma Secures NMPA Approval for Anrikefon in Hemodialysis\u2011Related Pruritus","datePublished":"2025-09-16T08:51:00+00:00","dateModified":"2025-09-16T08:51:02+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=41554"},"wordCount":258,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=41554#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1606.webp","keywords":["Haisco Pharmaceutical","Product approvals","SHE: 002653"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=41554#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=41554","url":"https:\/\/flcube.com\/?p=41554","name":"Haisco Pharma Secures NMPA Approval for Anrikefon in Hemodialysis\u2011Related Pruritus - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=41554#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=41554#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1606.webp","datePublished":"2025-09-16T08:51:00+00:00","dateModified":"2025-09-16T08:51:02+00:00","description":"Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) announced that the China National Medical Products Administration (NMPA) has granted additional approval for its Category\u202f1 innovative drug, Anrikefon Injection (trade name: Sishujing, development code: HSK21542). The new indication covers moderate\u2011to\u2011severe pruritus in adult patients with chronic kidney disease (CKD) undergoing maintenance hemodialysis.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=41554#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=41554"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=41554#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1606.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1606.webp","width":1080,"height":608,"caption":"Haisco Pharma Secures NMPA Approval for Anrikefon in Hemodialysis\u2011Related Pruritus"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=41554#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Haisco Pharma Secures NMPA Approval for Anrikefon in Hemodialysis\u2011Related Pruritus"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1606.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41554","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=41554"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41554\/revisions"}],"predecessor-version":[{"id":41557,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41554\/revisions\/41557"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/41556"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=41554"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=41554"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=41554"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}